Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지

Pharmacoeconomic Analysis of Tafluprost compared with Latanoprost on the Treatment of Primary open Angle Glaucoma or Ocular Hypertension in Korea

녹내장치료에 있어서 Tafluprost와 Latanoprost의 경제성평가

  • Kang, Suk-Hyun (Graduate School of Clinical Pharmacy, Sookmyung Wuomen's University) ;
  • Song, Hyun-Jin (Graduate School of Clinical Pharmacy, Sookmyung Wuomen's University) ;
  • Heo, Ji-Heong (Graduate School of Clinical Pharmacy, Sookmyung Wuomen's University) ;
  • Lee, Eui-Kyung (Graduate School of Clinical Pharmacy, Sookmyung Wuomen's University)
  • 강숙현 (숙명여자대학교 임상약학대학원) ;
  • 송현진 (숙명여자대학교 임상약학대학원) ;
  • 허지행 (숙명여자대학교 임상약학대학원) ;
  • 이의경 (숙명여자대학교 임상약학대학원)
  • Received : 2010.08.26
  • Accepted : 2010.12.01
  • Published : 2010.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

The main objective of this study is to evaluate the cost-effectiveness of tafluprost compared with latanoprost in primry open Angle Glaucoma (POAG) or ocular hypertension OH patients in Korea. A decision analytic model was developed from a societal perspective to estimate clinical outcome, drug cost and glaucoma related cost. The model assumes branch like following: successful treatment, switching to other drug, adding other drug, laser or surgery. Treatment success rate is defined as the percentage of patients with elevated IOP achieving <20% reduction, and discontinuation rate is the percentage of patients who were withdrawn due to severe adverse events. A model that is comprised of 1 month cycle length has 1 year. Treatment success rate and discontinuation rate were obtained from published literatures searched in database. Resource utilizations and costs were calculated with national health insurance data and clinical expert opinions. Sensitivity analyses were performed on crucial parameters. Tafluprost is less costly than latanoprost, $609.0 vs $651.2 expected cost. Thus tafluprost was shown to be dominant compared with latanoprost. The results of sensitivity analysis revealed stable across most of the included parameters. According to this study, tafluprost shows more clinical outcome for 1 year than latanoprost. In addition, first-line treatment of tafluprost is a more cost-minimizing strategy associated with POAG or OH compared with latanoprost.

Keywords

References

  1. 강자헌 : 정상 안압 녹내장 자료 : 선산 안과 연구 재단 http://www.cfer.co.kr/04e-09.htm (2004).
  2. Ikeda Y, Mori K, Ishibashi T, et al., Effects of switching from topical beta-blockers to latanoprost on intraocular pressure in patients with normal-tension glaucoma. J Ocul Pharmacol Ther, 2008; 24(2): 230-4 . https://doi.org/10.1089/jop.2007.0016
  3. He M, Foster PJ, GE J, et al., Prevalence and clinical characteristics of glaucoma in adult Chinese: a population-based study in Liwan district, Guangzhou. Invest Ophthalmol Vis Sci 2006; 47: 2782. https://doi.org/10.1167/iovs.06-0051
  4. Netland PA, Landry T, Sullivan EK, et al., Robertson SM, Davis AA; Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001; 132(4): 472-84. https://doi.org/10.1016/S0002-9394(01)01177-1
  5. Boyle JE, Ghosh K, Gieser DK, et al., A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Ophthalmology. 1999; 106 (12 Suppl): 10-6.
  6. Hommer A, Thygesen J, Ferreras A, et al., A European perspective on costs and cost effectiveness of ophthalmic combinations in the treatment of open-angle glaucoma. Eur J Ophthalmol. 2008; 18(5): 778-86. https://doi.org/10.1177/112067210801800519
  7. Hommer A, Wickstrom J, Friis MM, et al., A cost-effectiveness analysis of fixed-combination therapies in patients with open-angle glaucoma: a European perspective. Curr Med Res Opin. 2008; 24(4):1057-63. Epub. https://doi.org/10.1185/030079908X280626
  8. Lachaine J, Hodge WG, Steffensen I, et al., Prostaglandin analogues for ophthalmic use: a cost-effectiveness analysis. Can J Ophthalmol. 2008; 43(1): 33-41. https://doi.org/10.3129/I07-182
  9. Payet S, Denis P, Berdeaux G, et al., Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France. Clin Drug Investig. 2008; 28(3): 183-98. https://doi.org/10.2165/00044011-200828030-00005
  10. Goldberg LD, Walt J. Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications. Pharmacoeconomics. 2006; 24(3):251-64. https://doi.org/10.2165/00019053-200624030-00005
  11. Holmstrom S, Buchholz P, Walt J, et al., The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries. Curr Med Res Opin. 2006; 22(5): 897-905. https://doi.org/10.1185/030079906X104687
  12. Bernard LM, Althin R, Dhawan R, et al., Clinical and economic impacts of latanoprost 0.005% in first-line treatment of open-angle glaucoma and ocular hypertension in France. Eur J Ophthalmol. 2003; 13 Suppl 4: S30-43. https://doi.org/10.1177/112067210301304S04
  13. M. Cristina Leske, Anders Heijl, Leslie Hyman, Bo Bengtsson and Eugene Komaroff, Factors for progression and glaucoma treatment: The Early Manifest Glaucoma Trial. Current Opinion in Ophthalmology 2004; 15: 102-106. https://doi.org/10.1097/00055735-200404000-00008
  14. Burr JM, Mowatt G, Hernandez R, et al., The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation. Health Technol Assess. 2007; 11(41):iii-iv, ix-x, 1-190.
  15. Kuwayama Y, Komemusi S. Phase III confirmatory study of 0.0015% DE-085 (Tafluprost) ophthalmic solution as compared to 0.005% Latanoprost ophthalmic solution in patients with open-angle glaucoma or ocular hypertension.[ Japanese] Atarashii Ganka. 2008; 25: 1595-1602.
  16. Ikeda Y, Mori K, Ishibashi T, et al., Latanoprost nonresponders with open-angle glaucoma in the Japanese population. Jpn J Ophthalmol. 2006; 50(2): 153-7. https://doi.org/10.1007/s10384-005-0293-x
  17. 홍철, 박찬기, 김창식 : 외래 환자를 대상으로 한 녹내장 역학 조사 다기관 연구. 한국녹내장연구회(2006).
  18. Rylander NR, Vold SD. Cost analysis of glaucoma medications. Am J Ophthalmol. 2008; 145(1): 106-13. https://doi.org/10.1016/j.ajo.2007.08.041
  19. Lesk MR, Koulis T, Sampalis F, et al., Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension. Ann Pharmacother. 2008; 42(4):498-504. Epub 2008 Mar 25. https://doi.org/10.1345/aph.1K565
  20. Cantor LB, Hoop J, Katz LJ, et al., Alphagan/Betaxolol Clinical Success Study Group. Comparison of the clinical success and quality-of-life impact of brimonidine 0.2% and betaxolol 0.25% suspension in patients with elevated intraocular pressure. 2001; Clin Ther. 23(7): 1032-9. https://doi.org/10.1016/S0149-2918(01)80089-8
  21. DuBiner HB, Mroz M, Shapiro AM, et al., Brimonidine vs. Latanoprost Study Group. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial. 2001; Clin Ther. 23(12):1969-83. https://doi.org/10.1016/S0149-2918(01)80150-8